BioSpace News Archive

Mitate Zepto Technica inc. (CEO: Keisuke Harashima) has conducted performance simulations for the “RASEN” processor, which will be installed in a hardware accelerator, Relevant Patent Pending, dedicated to genome analysis under development, and obtained the world’s fastest processing results for whole human genome data analysis.

Prevencio, Inc. today announces presentation of highly accurate data on an Artificial Intelligence (AI)-driven blood test for Kawasaki disease (KD) at the Pediatric Academic Societies (PAS) International Sessions.

Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has received a response from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application that the study for selection and treatment of Prostate-Specific Membrane Antigen (PSMA) positive prostate cancers using 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA may proceed.

Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, today announces that it has entered into a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the protocol titled, “A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer (CATIQ P3).”

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it will participate in the virtual Benzinga Global Small Cap Conference

Omniscience today announced it has been granted a patent for technology that creates a breakthrough engine for Optical Character Recognition (OCR). Using innovative machine learning technology enables products based on this patent to handle a broader array of forms than more generic extraction tools such as those from Amazon, Google, or others.

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced the publication of the first cross-sectional, retrospective study to describe selective elevation of fast but not slow skeletal muscle fiber injury biomarkers in the blood of patients with Becker and Duchenne muscular dystrophy (BMD, DMD) in the journal, Muscle & Nerve

“All business areas achieved good performance in the first quarter, with very strong growth in Medical Solutions and Integrated Solutions,” said Nolato President and CEO Christer Wahlquist.

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is pleased to announce it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (NSCLC).

The vast majority of Canadians say vision loss is their most feared disability, yet 60 per cent experience symptoms of potential eye disease – and only half will see a healthcare professional about these symptoms, according to the Canadian Ophthalmological Society.